AGL 40.02 Increased By ▲ 0.02 (0.05%)
AIRLINK 127.30 Increased By ▲ 0.26 (0.2%)
BOP 6.62 Decreased By ▼ -0.05 (-0.75%)
CNERGY 4.48 Decreased By ▼ -0.03 (-0.67%)
DCL 8.60 Increased By ▲ 0.05 (0.58%)
DFML 41.65 Increased By ▲ 0.21 (0.51%)
DGKC 87.45 Increased By ▲ 0.60 (0.69%)
FCCL 32.55 Increased By ▲ 0.27 (0.84%)
FFBL 64.99 Increased By ▲ 0.19 (0.29%)
FFL 10.25 No Change ▼ 0.00 (0%)
HUBC 109.51 Decreased By ▼ -0.06 (-0.05%)
HUMNL 14.70 Increased By ▲ 0.02 (0.14%)
KEL 5.06 Increased By ▲ 0.01 (0.2%)
KOSM 7.63 Increased By ▲ 0.17 (2.28%)
MLCF 41.58 Increased By ▲ 0.20 (0.48%)
NBP 59.70 Decreased By ▼ -0.71 (-1.18%)
OGDC 192.84 Increased By ▲ 2.74 (1.44%)
PAEL 28.28 Increased By ▲ 0.45 (1.62%)
PIBTL 7.76 Decreased By ▼ -0.07 (-0.89%)
PPL 151.30 Increased By ▲ 1.24 (0.83%)
PRL 26.10 Decreased By ▼ -0.78 (-2.9%)
PTC 16.12 Increased By ▲ 0.05 (0.31%)
SEARL 83.25 Decreased By ▼ -2.75 (-3.2%)
TELE 7.80 Increased By ▲ 0.09 (1.17%)
TOMCL 35.40 Decreased By ▼ -0.01 (-0.03%)
TPLP 8.09 Decreased By ▼ -0.03 (-0.37%)
TREET 16.10 Decreased By ▼ -0.31 (-1.89%)
TRG 53.22 Decreased By ▼ -0.07 (-0.13%)
UNITY 26.37 Increased By ▲ 0.21 (0.8%)
WTL 1.26 No Change ▼ 0.00 (0%)
BR100 9,967 Increased By 83.6 (0.85%)
BR30 31,001 Increased By 400.7 (1.31%)
KSE100 94,120 Increased By 764.5 (0.82%)
KSE30 29,163 Increased By 232.1 (0.8%)

Scientists are taking the battle to prevent HIV to the next level with large-scale trials set to start using injections to protect vulnerable groups such as gay men and women in Africa for at least two months.
Further down the road, the hope is to produce matchstick-sized implants containing slow-release drugs - similar to existing under-the-skin contraceptive devices - that could offer year-long protection.
Companies with drugs involved include GlaxoSmithKline , Gilead Sciences and Merck. The initiatives build on the success of Gilead's once-daily pill Truvada, which has proved remarkably effective at stopping HIV infection during sex.
Clinical studies show such pre-exposure prophylaxis, or PrEP, can cut the risk of catching the virus by more than 90 percent, as long as people take their pills regularly. The problem is many do not.
Some women in trials in Africa, for example, said they were reluctant to have HIV tablets in the house for fear of what partners or neighbours would think.
An injection given in a clinic, experts argue, would add privacy and ensure steady drug levels. An implant in the arm might even combine contraception and HIV protection in one go.
"The more options there are the better and I think for some individuals injections will be great," said Jean-Michel Molina, professor of infectious diseases at Hospital Saint-Louis in Paris.
"Now that we know antiretrovirals have great potential to prevent HIV infections, it is time to really assess other ways to deliver these drugs."
The need remains acute. Despite treatment advances that have slashed AIDS deaths, around 1.9 million people still catch HIV each year - a number that hasn't budged since 2010. New infections among gay men are actually increasing.
The United Nations AIDS programme warned that the problem now threatened progress in ending the global epidemic, while the World Health Organisation has recommended PrEP for all groups at substantial risk of HIV infection.
GlaxoSmithKline's majority-owned ViiV Healthcare unit, working with US government agencies and the Bill & Melinda Gates Foundation, hopes to add the first injectable PrEP.
It plans to start a four-year trial as soon as next month testing its experimental drug cabotegravir in gay men in the Americas and Thailand, with a second trial next year assessing the medicine in African women.
Two separate studies evaluating cabotegravir in combination with another drug for HIV treatment were launched this month.
"The holy grail is a vaccine, but we don't have a vaccine yet," said Myron Cohen of the University of North Carolina at Chapel Hill, who is involved in the ViiV prevention study programme and believes new options can help rein in HIV.
He is also working on another prevention trial giving people antibodies via an intravenous drip.

Copyright Reuters, 2016

Comments

Comments are closed.